Treatment Information

Back

Prostate Cancer treatment details. Hormone.

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:San Francisco, CA
Treatments:HormoneHospital:UCSF Helen Diller Family Comprehensive Cancer Center
Drugs:Journal:Link
Date:Feb 2015

Description:

Patients:
This phase 3 study involved chemotherapy-naïve metastatic castration-resistant prostate cancer patients who were separated into two treatment groups. Group A consisted of 546 patients with a median age of 71 years. Group B had 542 patients with a median age of 70 years.

Treatment:
Patients in group A received hormone therapy with prednisone abiraterone acetate.

Patients in group B received hormone therapy with prednisone and a placebo.

Toxicities:
Cardiac adverse events that caused death were reported for group A. Grade 3 fluid retention/swelling and grade 4 liver toxicity were also reported.

Cardiac adverse events that caused death were reported for group B. Grade 3 fluid retention/swelling and grade 4 liver toxicity were also reported.

Results:
The median overall survival for groups A and B was 34.7 and 30.3 months, respectively.

Support:
This study was supported by Janssen Research & Development and many of the authors have received funding from several pharmaceutical companies.

Correspondence: Dr. Charles J Ryan; email: ryanc@medicine.ucsf.edu



Back